# Karuna Therapeutics, Inc. – Consensus ‘buy’ rating and 51.0% Upside Potential

- Link: https://www.directorstalkinterviews.com/karuna-therapeutics-inc.consensus-buy-rating-and-51.0-upside-potential/4121129662
- Published: 2023-10-13T13:53:12+01:00
- Author: Charlotte Edwards

**Karuna Therapeutics, Inc.** with ticker code (KRTX) have now 18 market analysts
covering the stock. The analyst consensus now points to a rating of ‘buy’. The range
between the high target price and low target price is between 332 and 197 suggesting
an average Analsyt target price of $271.11. Given that the stocks previous close
was at $179.49 this would indicate that there is a potential upside of 51.0%. Also
worth taking note is the 50 day moving average now sits at $176.88 and the 200 day
moving average is $196.53. The company has a market capitalization of 6.63B. The
stock price for the company is currently 176.14 USD

 The potential market cap would be $10,021,518,349 based on the market consensus.

The company has a dividend yield of 2.93%. Other points of data to note are a P/
E ratio of -, revenue per share of 0.17 and a -25.87% return on assets.

Karuna Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company
creates and delivers transformative medicines for people living with psychiatric
and neurological conditions. Its pipeline is primarily built on the therapeutic 
potential of its product candidate, KarXT (xanomeline-trospium), an oral modulator
of muscarinic receptors that are located both in the central nervous system (CNS),
and various peripheral tissues. KarXT combines xanomeline, a novel muscarinic agonist,
with trospium, an approved muscarinic antagonist, to preferentially stimulate muscarinic
receptors in the CNS. The Company is developing KarXT for the treatment of acute
psychosis in adults with schizophrenia, as well as for the treatment of psychosis
in Alzheimer’s disease (AD). The Company is also engaged in developing its investigational
TRPC4/5 candidate, KAR-2618, for the treatment of mood and anxiety disorders, and
plan to provide details regarding the expected development of KAR-2618.

Share on: